Adagio Therapeutics Inc
NASDAQ:ADGI
Intrinsic Value
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ADGI.
Fundamental Analysis
Balance Sheet Decomposition
Adagio Therapeutics Inc
| Current Assets | 376.9m |
| Cash & Short-Term Investments | 372m |
| Receivables | 377k |
| Other Current Assets | 4.5m |
| Non-Current Assets | 6.3m |
| PP&E | 6.1m |
| Other Non-Current Assets | 191k |
| Current Liabilities | 25m |
| Accounts Payable | 1.5m |
| Accrued Liabilities | 23.5m |
| Other Current Liabilities | 44k |
| Non-Current Liabilities | 2.2m |
| Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Adagio Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-230.7m
USD
|
|
Operating Income
|
-230.7m
USD
|
|
Other Expenses
|
-10.7m
USD
|
|
Net Income
|
-241.3m
USD
|
Free Cash Flow Analysis
Adagio Therapeutics Inc
What is Free Cash Flow?
ADGI Profitability Score
Profitability Due Diligence
Adagio Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Adagio Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ADGI Solvency Score
Solvency Due Diligence
Adagio Therapeutics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Adagio Therapeutics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADGI Price Targets Summary
Adagio Therapeutics Inc
Ownership
ADGI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ADGI Price
Adagio Therapeutics Inc
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -95% |
| Market Capitalization | 380.4m USD |
| Shares Outstanding | 109 740 000 |
| Percentage of Shares Shorted | 21.14% |
ADGI News
Last Important Events
Adagio Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Adagio Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The firm has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.
You don't have any saved screeners yet
